InflaRx NV
NASDAQ:IFRX
Relative Value
The Relative Value of one IFRX stock under the Base Case scenario is 5.64 USD. Compared to the current market price of 1.24 USD, InflaRx NV is Undervalued by 78%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
IFRX Competitors Multiples
InflaRx NV Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
DE |
InflaRx NV
NASDAQ:IFRX
|
76m USD | 1 076.2 | -1.6 | 0.4 | 0.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286.9B USD | 5.3 | 59.5 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
161B USD | 5.5 | 42.8 | 18.2 | 30 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.9B USD | 10.7 | 29.2 | 23.5 | 24.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.1B USD | 8.1 | 27.5 | 22.2 | 24.7 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.9B USD | 3 | 169.3 | 6.8 | 8.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
45.7B USD | 8.9 | -7.7 | -8.3 | -7.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.3 | 27.1 | 13.9 | 17.3 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |